Literature DB >> 27408351

The Successful Complete Remission Induction by Sorafenib Monotherapy in a FLT3-D835Y-Positive Patient with Refractory Acute Monocytic Leukemia.

Yanhua Yue1,2, Song Jin1,2, Ting Xu1,2, Jin Zhou1,2, Liang Ma1,2, Hongjie Shen1,2, Depei Wu1,2, Suning Chen1,2, Miao Miao1,2.   

Abstract

Sorafenib has been shown to be active in AML patients with FLT3-ITD. However, the effect of sorafenib in AML patients with FLT-TKD has never been well determined. Moreover, acquisition of secondary FLT3 TKD mutations, mainly at D835 (D835F/H/V/Y), are recognized as the major mechanisms of resistance of AML patients with FLT3-ITD to sorafenib. It has been reported that sorafenib induced death of cells that expressed the FLT3-ITD or FLT3-D835G but not cells that expressed the FLT3-D835Y point mutant or wild-type FLT3 in vitro. Here, we report the successful complete remission induction by sorafenib monotherapy in a FLT3-D835Y-positive patient with refractory AML-M5 followed by allogeneic stem cell transplantation.

Entities:  

Keywords:  Acute monocytic leukemia; Complete remission; FLT3-D835Y mutation; Sorafenib

Year:  2015        PMID： 27408351      PMCID： PMC4925519          DOI： 10.1007/s12288-015-0586-2

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN： 0971-4502            Impact factor:   0.900


  12 in total

1.  Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia.

Authors:  F M Abu-Duhier; A C Goodeve; G A Wilson; R S Care; I R Peake; J T Reilly
Journal:  Br J Haematol       Date:  2001-06       Impact factor: 6.998

2.  Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.

Authors:  Farhad Ravandi; Jorge E Cortes; Daniel Jones; Stefan Faderl; Guillermo Garcia-Manero; Marina Y Konopleva; Susan O'Brien; Zeev Estrov; Gautam Borthakur; Deborah Thomas; Sherry R Pierce; Mark Brandt; Anna Byrd; B Nebiyou Bekele; Keith Pratz; Rajyalakshmi Luthra; Mark Levis; Michael Andreeff; Hagop M Kantarjian
Journal:  J Clin Oncol       Date:  2010-03-08       Impact factor: 44.544

3.  Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.

Authors:  Y Yamamoto; H Kiyoi; Y Nakano; R Suzuki; Y Kodera; S Miyawaki; N Asou; K Kuriyama; F Yagasaki; C Shimazaki; H Akiyama; K Saito; M Nishimura; T Motoji; K Shinagawa; A Takeshita; H Saito; R Ueda; R Ohno; T Naoe
Journal:  Blood       Date:  2001-04-15       Impact factor: 22.113

4.  Internal tandem duplication of the flt3 gene found in acute myeloid leukemia.

Authors:  M Nakao; S Yokota; T Iwai; H Kaneko; S Horiike; K Kashima; Y Sonoda; T Fujimoto; S Misawa
Journal:  Leukemia       Date:  1996-12       Impact factor: 11.528

Review 5.  FLT3: ITDoes matter in leukemia.

Authors:  M Levis; D Small
Journal:  Leukemia       Date:  2003-09       Impact factor: 11.528

6.  Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.

Authors:  Sharyn D Baker; Eric I Zimmerman; Yong-Dong Wang; Shelley Orwick; Douglas S Zatechka; Jassada Buaboonnam; Geoffrey A Neale; Scott R Olsen; Eric J Enemark; Sheila Shurtleff; Jeffrey E Rubnitz; Charles G Mullighan; Hiroto Inaba
Journal:  Clin Cancer Res       Date:  2013-08-22       Impact factor: 12.531

7.  Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.

Authors:  Weiguo Zhang; Marina Konopleva; Yue-xi Shi; Teresa McQueen; David Harris; Xiaoyang Ling; Zeev Estrov; Alfonso Quintás-Cardama; Donald Small; Jorge Cortes; Michael Andreeff
Journal:  J Natl Cancer Inst       Date:  2008-01-29       Impact factor: 13.506

8.  Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial.

Authors:  Hubert Serve; Utz Krug; Ruth Wagner; M Cristina Sauerland; Achim Heinecke; Uta Brunnberg; Markus Schaich; Oliver Ottmann; Justus Duyster; Hannes Wandt; Thomas Fischer; Aristoteles Giagounidis; Andreas Neubauer; Albrecht Reichle; Walter Aulitzky; Richard Noppeney; Igor Blau; Volker Kunzmann; Reingard Stuhlmann; Alwin Krämer; Karl-Anton Kreuzer; Christian Brandts; Björn Steffen; Christian Thiede; Carsten Müller-Tidow; Gerhard Ehninger; Wolfgang E Berdel
Journal:  J Clin Oncol       Date:  2013-07-29       Impact factor: 44.544

9.  Sorafenib is tolerable and improves clinical outcomes in patients with FLT3-ITD acute myeloid leukemia prior to stem cell transplant and after relapse post-transplant.

Authors:  Sarah L Sammons; Keith W Pratz; B Douglas Smith; Judith E Karp; Ashkan Emadi
Journal:  Am J Hematol       Date:  2014-06-23       Impact factor: 10.047

10.  BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.

Authors:  Scott M Wilhelm; Christopher Carter; Liya Tang; Dean Wilkie; Angela McNabola; Hong Rong; Charles Chen; Xiaomei Zhang; Patrick Vincent; Mark McHugh; Yichen Cao; Jaleel Shujath; Susan Gawlak; Deepa Eveleigh; Bruce Rowley; Li Liu; Lila Adnane; Mark Lynch; Daniel Auclair; Ian Taylor; Rich Gedrich; Andrei Voznesensky; Bernd Riedl; Leonard E Post; Gideon Bollag; Pamela A Trail
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 13.312
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.